| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methicillin-Resistant Staphylococcus aureus | 9 | 2020 | 308 | 1.160 |
Why?
|
| Staphylococcal Infections | 9 | 2020 | 672 | 1.030 |
Why?
|
| Pleural Neoplasms | 3 | 2023 | 470 | 0.890 |
Why?
|
| Mesothelioma | 3 | 2023 | 544 | 0.840 |
Why?
|
| Bacteremia | 8 | 2019 | 689 | 0.770 |
Why?
|
| Republic of Korea | 14 | 2022 | 70 | 0.750 |
Why?
|
| Vibrio vulnificus | 3 | 2014 | 6 | 0.700 |
Why?
|
| Vibrio Infections | 3 | 2014 | 11 | 0.700 |
Why?
|
| Saliva | 1 | 2020 | 231 | 0.690 |
Why?
|
| Betacoronavirus | 2 | 2020 | 527 | 0.630 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 11 | 2019 | 2992 | 0.520 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.520 |
Why?
|
| Cefotaxime | 1 | 2014 | 34 | 0.500 |
Why?
|
| Ciprofloxacin | 1 | 2014 | 89 | 0.480 |
Why?
|
| Sepsis | 5 | 2016 | 652 | 0.460 |
Why?
|
| Vancomycin | 5 | 2017 | 273 | 0.460 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2013 | 317 | 0.450 |
Why?
|
| Dideoxynucleosides | 1 | 2013 | 19 | 0.450 |
Why?
|
| Lamivudine | 1 | 2013 | 28 | 0.450 |
Why?
|
| Zidovudine | 1 | 2013 | 40 | 0.450 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 61 | 0.440 |
Why?
|
| Staphylococcus aureus | 4 | 2019 | 548 | 0.430 |
Why?
|
| Transcriptome | 2 | 2019 | 1859 | 0.400 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 11538 | 0.370 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2022 | 2027 | 0.350 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 350 | 0.350 |
Why?
|
| Viral Load | 4 | 2020 | 493 | 0.320 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 7789 | 0.290 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2018 | 994 | 0.280 |
Why?
|
| Phosphoproteins | 3 | 2015 | 1152 | 0.260 |
Why?
|
| Liver Neoplasms | 5 | 2022 | 4557 | 0.260 |
Why?
|
| RNA, Viral | 3 | 2023 | 671 | 0.250 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 1439 | 0.250 |
Why?
|
| Prospective Studies | 10 | 2023 | 12873 | 0.230 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2019 | 519 | 0.230 |
Why?
|
| Thymus Neoplasms | 2 | 2019 | 400 | 0.220 |
Why?
|
| Stomach Neoplasms | 3 | 2023 | 2278 | 0.220 |
Why?
|
| HIV Infections | 2 | 2013 | 2134 | 0.220 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 2864 | 0.210 |
Why?
|
| Humans | 51 | 2023 | 261506 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5319 | 0.210 |
Why?
|
| Virulence Factors | 2 | 2020 | 213 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 541 | 0.200 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2021 | 25 | 0.200 |
Why?
|
| Methicillin | 2 | 2017 | 49 | 0.190 |
Why?
|
| Salvage Therapy | 1 | 2009 | 2054 | 0.190 |
Why?
|
| Natural Killer T-Cells | 2 | 2012 | 124 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 198 | 0.190 |
Why?
|
| Cross Infection | 4 | 2018 | 544 | 0.190 |
Why?
|
| Asymptomatic Infections | 1 | 2020 | 34 | 0.180 |
Why?
|
| Nasopharynx | 1 | 2020 | 119 | 0.180 |
Why?
|
| Pneumonia | 2 | 2017 | 751 | 0.180 |
Why?
|
| Viral Vaccines | 1 | 2022 | 304 | 0.180 |
Why?
|
| Scrub Typhus | 1 | 2019 | 1 | 0.170 |
Why?
|
| Bunyaviridae Infections | 1 | 2019 | 7 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 476 | 0.170 |
Why?
|
| Povidone-Iodine | 1 | 2019 | 21 | 0.170 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 489 | 0.170 |
Why?
|
| Korea | 4 | 2018 | 63 | 0.170 |
Why?
|
| beta-Lactams | 1 | 2018 | 53 | 0.160 |
Why?
|
| Endocarditis, Bacterial | 1 | 2019 | 128 | 0.160 |
Why?
|
| Aged | 20 | 2020 | 70117 | 0.160 |
Why?
|
| CTLA-4 Antigen | 2 | 2023 | 657 | 0.160 |
Why?
|
| Daptomycin | 1 | 2017 | 39 | 0.150 |
Why?
|
| Female | 29 | 2022 | 141928 | 0.150 |
Why?
|
| Middle Aged | 21 | 2020 | 86204 | 0.150 |
Why?
|
| Calcitonin | 1 | 2018 | 186 | 0.150 |
Why?
|
| Phlebotomus Fever | 1 | 2016 | 1 | 0.150 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 1022 | 0.150 |
Why?
|
| Tick-Borne Diseases | 1 | 2016 | 9 | 0.150 |
Why?
|
| Pandemics | 3 | 2022 | 1559 | 0.150 |
Why?
|
| Bile Duct Neoplasms | 1 | 2022 | 493 | 0.140 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2018 | 181 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 1217 | 0.140 |
Why?
|
| Adult | 18 | 2023 | 77950 | 0.140 |
Why?
|
| Young Adult | 7 | 2020 | 21445 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 2315 | 0.140 |
Why?
|
| Genomics | 4 | 2023 | 2738 | 0.140 |
Why?
|
| Amino Acid Transport Systems | 1 | 2015 | 15 | 0.140 |
Why?
|
| Mesoderm | 1 | 2018 | 404 | 0.140 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.140 |
Why?
|
| Male | 25 | 2022 | 123000 | 0.140 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 285 | 0.130 |
Why?
|
| Virus Shedding | 3 | 2023 | 88 | 0.130 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2018 | 297 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2019 | 1048 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 481 | 0.130 |
Why?
|
| Cell Death | 2 | 2014 | 671 | 0.120 |
Why?
|
| Bacterial Proteins | 1 | 2020 | 1029 | 0.120 |
Why?
|
| Organophosphonates | 1 | 2015 | 64 | 0.120 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 29902 | 0.120 |
Why?
|
| Levofloxacin | 1 | 2014 | 57 | 0.120 |
Why?
|
| Paratyphoid Fever | 1 | 2014 | 2 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2017 | 829 | 0.120 |
Why?
|
| Dysentery, Bacillary | 1 | 2014 | 11 | 0.120 |
Why?
|
| Typhoid Fever | 1 | 2014 | 16 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 8873 | 0.120 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 149 | 0.120 |
Why?
|
| Cholera | 1 | 2014 | 27 | 0.120 |
Why?
|
| Cytosine | 1 | 2015 | 141 | 0.120 |
Why?
|
| Teicoplanin | 1 | 2013 | 6 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2018 | 479 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 383 | 0.120 |
Why?
|
| BK Virus | 1 | 2015 | 123 | 0.120 |
Why?
|
| Cystitis | 1 | 2015 | 107 | 0.120 |
Why?
|
| Polyomavirus Infections | 1 | 2015 | 139 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 2314 | 0.120 |
Why?
|
| Tumor Virus Infections | 1 | 2015 | 224 | 0.120 |
Why?
|
| Raltegravir Potassium | 1 | 2013 | 3 | 0.110 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 395 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2014 | 181 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 1265 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 228 | 0.110 |
Why?
|
| Multiple Myeloma | 2 | 2014 | 2138 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2018 | 620 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2018 | 5542 | 0.110 |
Why?
|
| RNA, Untranslated | 1 | 2014 | 237 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 10331 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1870 | 0.100 |
Why?
|
| Treatment Outcome | 9 | 2021 | 32848 | 0.100 |
Why?
|
| Escherichia coli Infections | 1 | 2014 | 241 | 0.100 |
Why?
|
| Adolescent | 6 | 2020 | 31252 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2014 | 333 | 0.100 |
Why?
|
| Risk Factors | 8 | 2023 | 17523 | 0.100 |
Why?
|
| Bacterial Load | 1 | 2010 | 46 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2013 | 621 | 0.100 |
Why?
|
| Oncogenes | 1 | 2014 | 673 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2014 | 1643 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 446 | 0.090 |
Why?
|
| Animals | 8 | 2021 | 59536 | 0.090 |
Why?
|
| Proteomics | 3 | 2023 | 1380 | 0.090 |
Why?
|
| Apoptosis | 2 | 2021 | 7591 | 0.090 |
Why?
|
| Linezolid | 1 | 2009 | 64 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2014 | 636 | 0.090 |
Why?
|
| Carbapenems | 1 | 2009 | 62 | 0.090 |
Why?
|
| Prognosis | 8 | 2020 | 21713 | 0.090 |
Why?
|
| Oxazolidinones | 1 | 2009 | 60 | 0.090 |
Why?
|
| Time Factors | 4 | 2020 | 12926 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2019 | 3341 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1546 | 0.080 |
Why?
|
| Lipids | 1 | 2013 | 644 | 0.080 |
Why?
|
| Aminoglycosides | 1 | 2009 | 220 | 0.080 |
Why?
|
| Acetamides | 1 | 2009 | 113 | 0.080 |
Why?
|
| DNA, Bacterial | 1 | 2010 | 558 | 0.080 |
Why?
|
| Phlebovirus | 2 | 2019 | 2 | 0.080 |
Why?
|
| Algorithms | 1 | 2019 | 3890 | 0.080 |
Why?
|
| Kinetics | 2 | 2022 | 2049 | 0.080 |
Why?
|
| Vaccination | 3 | 2022 | 1123 | 0.080 |
Why?
|
| Methicillin Resistance | 2 | 2019 | 147 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 5159 | 0.080 |
Why?
|
| HIV-1 | 1 | 2013 | 653 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 4549 | 0.080 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 1320 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 598 | 0.080 |
Why?
|
| Mice | 5 | 2021 | 34495 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2015 | 1230 | 0.080 |
Why?
|
| Syphilis | 1 | 2008 | 61 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2017 | 9180 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2021 | 37905 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 3154 | 0.070 |
Why?
|
| Phenotype | 4 | 2022 | 6295 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2012 | 548 | 0.070 |
Why?
|
| Smallpox Vaccine | 1 | 2005 | 43 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 1538 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2022 | 9244 | 0.060 |
Why?
|
| Immunocompromised Host | 2 | 2023 | 698 | 0.060 |
Why?
|
| Incidence | 4 | 2017 | 5673 | 0.060 |
Why?
|
| Streptogramins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 14551 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 10001 | 0.060 |
Why?
|
| Macrolides | 1 | 2004 | 62 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 3251 | 0.060 |
Why?
|
| Hospitals | 2 | 2018 | 485 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2019 | 2316 | 0.050 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2004 | 202 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 172 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2018 | 6100 | 0.050 |
Why?
|
| Neoplasms | 2 | 2017 | 15193 | 0.050 |
Why?
|
| Ribs | 1 | 2021 | 91 | 0.050 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 143 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 3168 | 0.050 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 14289 | 0.050 |
Why?
|
| Sex Factors | 2 | 2018 | 2139 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 222 | 0.050 |
Why?
|
| Umbilical Veins | 1 | 2019 | 115 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2022 | 334 | 0.040 |
Why?
|
| Orientia tsutsugamushi | 1 | 2019 | 1 | 0.040 |
Why?
|
| Adhesins, Bacterial | 1 | 2019 | 85 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 164 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 3441 | 0.040 |
Why?
|
| Fibronectins | 1 | 2019 | 197 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 3578 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2015 | 1555 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 2019 | 147 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4298 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 966 | 0.040 |
Why?
|
| Gene Expression | 2 | 2017 | 3570 | 0.040 |
Why?
|
| Leukopenia | 1 | 2019 | 151 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 688 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 10035 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 978 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 5437 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 121 | 0.040 |
Why?
|
| Cell Wall | 1 | 2017 | 46 | 0.040 |
Why?
|
| Reagent Strips | 1 | 2017 | 8 | 0.040 |
Why?
|
| Vancomycin Resistance | 1 | 2017 | 54 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6207 | 0.040 |
Why?
|
| Transcription Factors | 3 | 2015 | 5270 | 0.040 |
Why?
|
| Ticks | 1 | 2016 | 32 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 6550 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2018 | 179 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 347 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 400 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2016 | 209 | 0.030 |
Why?
|
| Age Factors | 2 | 2017 | 5377 | 0.030 |
Why?
|
| Heterografts | 1 | 2018 | 733 | 0.030 |
Why?
|
| Seasons | 1 | 2016 | 340 | 0.030 |
Why?
|
| Stem Cells | 1 | 2022 | 1213 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 974 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 265 | 0.030 |
Why?
|
| Enterohemorrhagic Escherichia coli | 1 | 2014 | 9 | 0.030 |
Why?
|
| Antibodies | 1 | 2017 | 838 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2018 | 11965 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 249 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 497 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 846 | 0.030 |
Why?
|
| Mutation | 3 | 2018 | 15179 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 527 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 750 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 472 | 0.030 |
Why?
|
| Pain | 1 | 2021 | 1658 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 543 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2014 | 362 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 5178 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 973 | 0.030 |
Why?
|
| Galactosylceramides | 1 | 2012 | 34 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 1487 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 1972 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 543 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 633 | 0.030 |
Why?
|
| Pyrazines | 1 | 2014 | 495 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 3203 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2019 | 2086 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 837 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2019 | 5637 | 0.020 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 669 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 1274 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2014 | 7226 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 1516 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3890 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 4975 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 2307 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3472 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 2843 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 2083 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 2352 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2014 | 1026 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6009 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 4917 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4320 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12221 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 1399 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6089 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5047 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 3033 | 0.020 |
Why?
|
| Vaccinia virus | 1 | 2005 | 79 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2005 | 110 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2005 | 299 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 1546 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2005 | 409 | 0.020 |
Why?
|
| Lincosamides | 1 | 2004 | 1 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 2669 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 4053 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 1259 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 4109 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 15862 | 0.010 |
Why?
|